SCHEMBL3208754

SCHEMBL3208754

CCCN(C)CCC(=O)O.NC(=O)N1CCCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 10/20 0.44
KDM5A P29375 8/20 0.44
KDM5C P41229 1/20 0.38
KDM5B Q9UGL1 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
PHF8 Q9UPP1 2/20 0.37
KDM4A O75164 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
FFAR3 O14843 1/20 0.32
HDAC3 O15379 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC8 Q9BY41 1/20 0.32
ITGB3 P05106 1/20 0.32
ITGA2B P08514 1/20 0.32
F2R P25116 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3206918 0.98 KDM4C (0.43) KDM4CKDM5AKDM5CKDM5BL3MBTL1
SCHEMBL3197750 0.98 KDM4C (0.43) KDM4CKDM5AKDM5CKDM5BL3MBTL1
SCHEMBL3211249 0.89 KDM4C (0.43) KDM4CKDM5AKDM5CKDM5BL3MBTL1
SCHEMBL3195870 0.88 KDM5A (0.42) KDM4CKDM5AKDM5CKDM5BL3MBTL1
SCHEMBL3203923 0.88 KDM5A (0.42) KDM4CKDM5AKDM5CKDM5BL3MBTL1
SCHEMBL3206435 0.86 L3MBTL1 (0.39) KDM4CKDM5AL3MBTL1PHF8MEN1
SCHEMBL3213464 0.84 L3MBTL1 (0.40) KDM4CKDM5AL3MBTL1PHF8MEN1
SCHEMBL3196933 0.84 L3MBTL1 (0.40) KDM4CKDM5AL3MBTL1PHF8MEN1
SCHEMBL3197130 0.83 KDM4A (0.38) KDM4CKDM5AL3MBTL1PHF8KDM4A
SCHEMBL3204014 0.83 KDM5A (0.39) KDM4CKDM5AL3MBTL1PHF8MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8937090-B2 Parakeratosis inhibitor, pore-shrinking agent and external composition for skin SHISEIDO COMPANY, LTD. (JP) 2015-01-20 US disclosed
US-20120232111-A1 Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin SHISEIDO COMPANY, LTD. (JP) 2012-09-13 US disclosed
US-20120165409-A1 WRINKLE-IMPROVING AGENT SHISEIDO COMPANY, LTD. (JP) 2012-06-28 US disclosed
US-20100035881-A1 WRINKLE-IMPROVING AGENT SHISEIDO COMPANY, LTD. (JP) 2010-02-11 US disclosed
EP-1941861-A1 WRINKLE-IMPROVING AGENT Shiseido Company, Limited (JP) 2008-07-09 EP disclosed
EP-1880711-A1 PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN Shiseido Company, Limited (JP) 2008-01-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035881-A1 WRINKLE-IMPROVING AGENT AAAS, GLA, COL14A1 KDM4C 4349/4885KDM5A 4278/4885KDM5C 4210/4885
US-20120232111-A1 Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin CUTA, AAAS, NUP160 KDM4C 4476/4885KDM5A 4697/4885KDM5C 4786/4885
US-20120165409-A1 WRINKLE-IMPROVING AGENT AAAS, GLA, COL14A1 KDM4C 4459/4885KDM5A 4370/4885KDM5C 4389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.